Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACAM1000 Dose-Response Study
NCT00053508Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Sep 2002
- Primary completion
- Mar 2003
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ACAM1000 in smallpox, sponsored by Sanofi. Started Sep 2002; status: terminated.
02
Drugs
ACAM1000
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00053508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053508.